drugset / Trial / NCT05739916

Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

NCT05739916 ↗

Phase 1 Unknown 34 enrolled Dong-A ST Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229\_01(5/1000 mg x1 tablets) at fed state.

Timeline

Start
2023-03-30
Primary completion
2023-04-28
Completion
2023-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-1229_01 Unknown — —

Indications

No indication recorded.